




Scientific Committee on Consumer Safety

SCCS

OPINION ON
4-Nitrophenyl aminoethylurea

COLIPA n° B70



The SCCS adopted this opinion at its 8th plenary meeting
of 21 September 2010

About the Scientific Committees

Three independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat. They are: the Scientific Committee on Consumer Safety (SCCS), the Scientific Committee on Health and Environmental Risks (SCHER) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) and are made up of external experts.

In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Evaluation Agency (EMA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA).

SCCS

The Committee shall provide opinions on questions concerning all types of health and safety risks (notably chemical, biological, mechanical and other physical risks) of non-food consumer products (for example: cosmetic products and their ingredients, toys, textiles, clothing, personal care and household products such as detergents, etc.) and services (for example: tattooing, artificial sun tanning, etc.).

Scientific Committee members

Jürgen Angerer, Ulrike Bernauer, Claire Chambers, Qasim Chaudhry, Gisela Degen, Thomas Platzek, Suresh Chandra Rastogi, Vera Rogiers, Christophe Rousselle, Tore Sanner, Kai Savolainen, Jacqueline Van Engelen, Maria Pilar Vinardell, Rosemary Waring, Ian R. White

Contact

European Commission
Health & Consumers
Directorate C: Public Health and Risk Assessment
Unit C7 - Risk Assessment
Office: B232 B-1049 Brussels
Sanco-Sc6-Secretariat@ec.europa.eu

© European Union, 2010

ISSN 1831-4767
doi:10.2772/28480

ISBN 978-92-79-12757-1
ND-AQ-09-027-EN-N

The opinions of the Scientific Committees present the views of the independent scientists who are members of the committees. They do not necessarily reflect the views of the European Commission. The opinions are published by the European Commission in their original language only.

http://ec.europa.eu/health/scientific_committees/consumer_safety/index_en.htm

ACKNOWLEDGMENTS

Prof. J. Angerer

Dr. C. Chambers

Prof. T. Platzek

(chairman)

Dr. S.C. Rastogi

Dr. C. Rousselle

Prof. T. Sanner

Dr. J. van Benthem

(associate scientific advisor) (rapporteur)

Prof. M.P. Vinardell

Dr. I.R. White

External experts

Dr. Mona-Lise Binderup National Food Institute, Denmark

Keywords: SCCS, scientific opinion, hair dye, B70, 4-nitrophenyl aminoethylurea, directive 76/768/ECC, CAS 27080-42-8, EC 410-700-1

Opinion to be cited as: SCCS (Scientific Committee on Consumer Safety), Opinion on 4-nitrophenyl aminoethylurea, 21 September 2010

TABLE OF CONTENTS

ACKNOWLEDGMENTS	3
1. BACKGROUND	5
2. TERMS OF REFERENCE.....	5
3. OPINION.....	6
4. CONCLUSION	27
5. MINORITY OPINION.....	27
6. REFERENCES	28

1. BACKGROUND

Submission I for 4-Nitrophenyl aminoethylurea was submitted in March 1990 by COLIPA¹ according to COLIPA.

A first scientific opinion (SPC/106/92) was adopted the 2 of June 1992.

Submission II was submitted in July 2005 by COLIPA.

The second scientific opinion (SCCP/1037/06) was adopted 19 June 2007 with the conclusion "*that the information submitted is insufficient to allow a final risk assessment to be carried out. An additional mutagenicity / genotoxicity test should be performed following the relevant SCCNFP/SCCP opinions and in accordance with its Notes of Guidance in order to exclude its gene mutation potential.*

4-Nitrophenyl aminoethylurea is a secondary amine. It should not be used in combination with nitrosating substances. The nitrosamine content should be < 50 ppb. Its stability in the presence of hydrogen peroxide should be demonstrated."

According to this submission 4-Nitrophenyl aminoethylurea is used as:

- a) a non-reactive hair colouring agent ("direct dye") in semi-permanent hair dye formulations at a maximum on-head concentration of 0.5%.
- b) a non-reactive hair colouring agent ("direct dye") in oxidative hair dye formulations at a maximum on-head concentration of 0.25%.

The substance is currently regulated in annex III, part 2 under entry 49 on the list of substances, provisionally allowed, which cosmetic products must not contain except subject to restrictions and conditions laid down until 31.12.2010.

The current submission III on 4-nitrophenyl aminoethylurea is a response to the opinion SCCP/1037/06 and it contains an *in vivo* UDS study.

2. TERMS OF REFERENCE

1. *Does SCCS consider 4-Nitrophenyl aminoethylurea safe for use as a non-oxidative hair dye with an on-head concentration of maximum 0.5% taken into account the scientific data provided?*
2. *Does SCCS consider 4-Nitrophenyl aminoethylurea safe for use in oxidative hair dye formulations with an on-head concentration of maximum 0.25% taken into account the scientific data provided?*
3. *And/or does the SCCS have any further concerns with regard to the use of 4-Nitrophenyl aminoethylurea in any hair dye formulation?*

¹ COLIPA – The European Cosmetics Association

3. OPINION

3.1. Chemical and Physical Specifications

The name mentioned in the opinion of 2 June 1992 (SPC/106/92) was 1-(2'-ureidoethyl)-amino-4-nitro-benzene. Ureidogelb is one of the trade names.

3.1.1. Chemical identity

3.1.1.1. Primary name and/or INCI name

4-Nitrophenyl aminoethylurea (INCI)

3.1.1.2. Chemical names

Urea, 2-[(4-nitrophenyl)amino]ethyl-, (CA Index name, 9CI)
N-[2-(4-nitroanilino)ethyl]-urea (IUPAC)


3.1.1.3. Trade names and abbreviations

Ureidogelb
Nitrogelb (OSL)
COLIPA n° B070

3.1.1.4. CAS / EC number

CAS: 27080-42-8
EC: 410-700-1

3.1.1.5. Structural formula



3.1.1.6. Empirical formula

Formula: C₉H₁₂N₄O₃

3.1.2. Physical form

Yellow powder

3.1.3. Molecular weight

Molecular weight: 224.22 g/mol

Opinion on 4-nitrophenyl aminoethylurea

3.1.4. Purity, composition and substance codes

Purity and impurities of various batches of 4-Nitrophenyl aminoethylurea

Description	Batch number					
	Ch. B1/89	Ch. B3/89	Ch. L4/130	LEH 5/2	L 4/113	Ch. 110889 (R960038 05)
Identification /characterisation	NMR, HPLC	NMR, MS, HPLC, IR, UV_Vis	NMR, HPLC, Elemental analysis	NMR, MS, HPLC, IR, UV_Vis,	NMR, HPLC	NMR, MS, IR, UV_Vis, HPLC, Elemental analysis
NMR content (g/100 g)	99.5	96.5	92.7	96.8	98.0	99.5
HPLC content* (g/100g)	97.5	98.1	91.6	95.2	99.2	Reference material
Impurities** A(ppm) B (g/100 g)	<100 ¹ 0.113	<50 ¹ 0.05	<50 ¹ 0.12	<50 ¹ 1.06	<50 ¹ 0.18	<50 ¹ 0.22
Water content (g/100g)	0.02	0.01	6.7	0.07	0.04	0.02
Loss on drying	0.03	0.02	6.6	0.10	0.01	0.01
Residue on ignition (g/100 g)	0.05	0.07	0.09	2.37	0.05	0.15
Element screening, ppm Levels above 25 ppm are reported		Si 91 K 236 Fe 18	Na 40 Mg 39 Si 241 K 98 Ca 171 Fe 46	Na 52 Si 117 K 26300 Fe 20	Si 34	Si 34 K 527

* Reference material Ch. 110889 (R96003805)

** A: 1-chloro-4-nitrobenzene

B: N-(2-aminoethyl)-4-nitroaniline

Several impurities (other than A and B) with HPLC peak area 0.01-0.3% were observed in the attached chromatograms. These were tentatively identified as derivatives of 4-Nitrophenyl aminoethylurea

¹ Detection limit, not detected

3.1.5. Impurities / accompanying contaminants

See 3.1.4

3.1.6. Solubility

Water:	0.0787 g/l, at 21°C, pH 8.1(saturated solution)
Ethanol:	< 10 g/l
DMSO:	>100 g/l
Acetone/water 1:1:	<10 g/l

3.1.7. Partition coefficient (Log P_{ow})

Log P_{ow}: 0.88 (pH 7.7, 22°C)

3.1.8. Additional physical and chemical specifications

Melting point:	180.9 °C (decomposition during melting)
Boiling point:	not applicable
Flash point:	/
Vapour pressure:	17.4 hPa (20°C)
Density:	0.636 (20°C)

Opinion on 4-nitrophenyl aminoethylurea

Viscosity: /
 pKa: /
 Refractive index: /
 UV_Vis spectrum: λmax at 381 nm and 230 nm

3.1.9. Stability

4-Nitrophenyl aminoethylurea on storage in dryness and protected from light is considered to be stable for 7 years.

4-Nitrophenyl aminoethylurea in a prototype oxidative hair dye cream formulation was shown to be stable for 6 months (recovery 94%). No information was provided concerning any degradation product of 4-Nitrophenyl aminoethylurea in the formulation.

4-Nitrophenyl aminoethylurea was shown to be stable, for 45 min test period, in an oxidative hair dye formulation mixed with hydrogen peroxide (recovery 94%).

The stability of test solution was tested over a period of 7 days. The test solutions were stored at room temperature and protected from light.

DMSO solution (approx. 10% w/v):	Stable, 99.5-100.5% of initial concentration
Acetone/water 1:1 solution (approx. 0.25%, w/v):	Stable, 98.5-99.5% of initial concentration
Water solution (approx. 0.01% w/v):	Stable, 99.7-101.0% of initial concentration

General comment to physico-chemical characterisation

- 4-Nitrophenyl aminoethylurea is a secondary amine, and thus, it is prone to nitrosation. Nitrosamine content in 4-nitrophenyl aminoethylurea is not reported.
- > 1% N-(2-aminoethyl)-4 nitroaniline was detected in batch LEH5/2. This substance is a secondary amine. (*The applicant stated that LEH5/2 is an old batch from 1983*) The content of N-(2-aminoethyl)-4 nitroaniline in other batches was <0.22%

3.2. Function and uses

4-Nitrophenyl aminoethylurea is used as direct dye in semi-permanent hair formulations at a maximum on-head concentration of 0.5%.

4-Nitrophenyl aminoethylurea is used as a hair colouring agent (direct dye) in oxidative hair dye formulations at a maximum on-head concentration of 0.25%.

3.3. Toxicological Evaluation

3.3.1. Acute toxicity

3.3.1.1. Acute oral toxicity

Guideline:	Not indicated but in line with OECD 401(1981)
Species/strain:	Rat, Wistar strain Mice, CF1
Test substance:	1-(2-ureidoethyl)-amino-4-nitrobenzene
Batch:	Ch. L4/130
Purity:	91.6% (HPLC)
Dose:	Rats: 6000 and 8000 mg/kg bw Mice: 4200, 6600, 9000 and 11400 mg/kg bw
GLP:	Not in compliance

The test substance suspended in a 10% gummi Arabicum solution was administered at 4 dose levels from 4200 to 11400 mg/kg bw to 10 female CF1 mice per dose and at 6000 and 8000 mg/kg bw to 6 Wistar rats per sex and dose once by oral gavage. Mortality and clinical signs were checked daily for the 14-day observation period. Body weights were recorded weekly and all animals were submitted to a gross necropsy at the end of the observation period.

Results

In the main experiment clinical signs such as reduced activity and clonic-tonic spasms were noted in the mice at doses of 9000 and 11400 mg/kg bw within the first four hours after substance administration. In the rats, no clinical signs were observed. Animals died within 2-24 hours (CF1 mice) and between 3 and 7 days (Wistar rats) after substance administration. At necropsy, no macroscopic organ changes/damages were noted.

Based on the observed mortality rates, the following LD₅₀'s were calculated using the method of Spearman-Kärber:

LD ₅₀ rat (female):	8 g/kg bw
LD ₅₀ rat (male):	> 8 g/kg bw
LD ₅₀ mouse (female):	7.32 g/kg bw

Ref.: 16

Comment

Although the study was not performed in compliance with GLP, the results are considered valuable for the evaluation of the acute oral toxicity of the test substance.

3.3.1.2. Acute dermal toxicity

Guideline:	OECD 402 (1981) (limit test)
Species/strain:	Rat, strain Sprague Dawley (Him:OFA, SPF), 5/sex
Test substance:	Nitrogelb
Batch:	B1/89
Purity:	99.0 area% (HPLC, 254 nm)
Dose level:	2000 mg/kg bw
Observation period:	14 days
GLP:	In compliance

The test substance was moistened with distilled water immediately before testing, and was administered to the dorsal skin of 5 male and 5 female young-adult Sprague Dawley rats (Him:OFA, SPF), clipped free of hair the day before. The treated area of 30 cm²

(corresponding to at least 10% of the body surface) was covered by a cellulose patch and kept in place by a tape. The area was covered additionally by a Fixomull dressing. After 24 hours exposure, the dressing, tape and patch were removed and residual test substance was wiped off. Clinical signs were noted at 10, 30 min, 1, 2, 4 and 6 hours after administration and at least once daily for the remaining 2 week observation period. Body weight was determined before administration and on days 7 and 14 after administration of the test substance.

Results

All animals survived until the end of the observation period. The body weight gain was reduced in 2 females during the second week as compared to untreated animals.

Slight and temporary clinical signs, such as chromodacryorrhoea, were noted in 2 males and 1 female within 1 day after administration. Yellow stained fur was observed in 1 male and all females post mortem.

Conclusion

The acute dermal toxicity study with 4-nitrophenylaminoethylurea in 5 male and 5 female rats revealed a dermal LD₅₀ of > 2000 mg/kg bw.

Ref.: 17

3.3.1.3. Acute inhalation toxicity

No data submitted

3.3.2 Irritation and corrosivity

3.3.2.1. Skin irritation

Guideline:	/
Species:	Rabbit, New Zealand White
Group:	3 males
Substance:	Nitrogelb
Batch:	B1/89
Purity:	97.5%
Dose:	0.5g (moistened with water), single dermal application, 4h, semi-occlusive
GLP:	In compliance

0.5g of Nitrogelb moistened with distilled water was applied to an area of about 6.25cm² clipped dorsal skin of each of 3 male New Zealand White rabbits and kept in contact with the skin for 4 hours under semi-occlusive conditions. The treated area was covered with gauze and Micropore tape and then loosely bound with an elastic bandage.

The effects on the skin were evaluated at 1, 24, 48 and 72 h after patch removals.

Results

In one of the rabbits there was a slight erythema at 1 h after patch removal. No other reaction was observed at any other time point.

Conclusion

Under the conditions of the study, nitrogelb was not irritant to rabbit skin.

Ref.: 18

3.3.2.2. Mucous membrane irritation

Guideline:	/
Species:	Rabbit, New Zealand White
Group:	3 males

Opinion on 4-nitrophenyl aminoethylurea

Substance: Nitrogelb
 Batch: B1/89
 Purity: 97.5%
 Dose: 100mg (undiluted), instilled into the right conjunctival sac.
 GLP: In compliance

100mg of Nitrogelb (undiluted) was instilled into the conjunctival sac of the right eye of 3 male New Zealand White rabbits without rinsing. The left eye served as the control. The effects on the eyes were evaluated at 1, 24, 48 and 72 h after application and at day 7.

Results

No corneal lesions were noted at any reading.

A slight iritis was noted in 2 animals 24 h after application, which had resolved at 48 h. Slight to moderate conjunctival erythema was noted in all animals at up to 48 h and up to 72 h in 2 animals. At 7 days, no abnormality was observed.

Conclusion

Under the conditions of the study, nitrogelb was irritant to rabbit eyes.

Ref.: 19

3.3.3. Skin sensitisation

In a former submission, three Magnusson/Kligman tests with 4-nitrophenylaminoethylurea were described. These tests were considered as negative although there were limitations with regard to the test design and/or material used. They do not contribute to the hazard identification of 4-nitrophenyl aminoethylurea.

LLNA

Guideline: OECD 429
 Species: Mouse, strain CBA/J
 Group: 5 females per concentration
 Substance: 4-nitrophenyl aminoethylurea (WR23348)
 Batch: 110889
 Purity: 99.5%
 Dose: 0.5, 1.5, 5.0 and 10% (w/v) in DMSO
 Control: negative – DMSO alone; positive - p-phenylenediamine 1% in DMSO
 GLP: In compliance

The skin sensitising potential of 4-nitrophenylaminoethylurea was investigated in 5 female CBA/J mice per concentration by measuring the cell proliferation in the draining lymph nodes after topical application to the ear.

25 µl of 0 (vehicle only), 0.5, 1.5, 5 and 10% of 4-nitrophenylaminoethylurea in DMSO were applied to the surface of the ear of five female CBA/J mice per group for three consecutive days. After application, the ears were dried by means of a hair dryer for about 5 minutes. As positive control, p-phenylenediamine (PPD) at 1% in DMSO was investigated in parallel under identical test conditions.

Animals were checked for morbidity/mortality at least once daily. Observation for clinical signs was performed daily before and at least once after dosing. Body weight was determined at day -1 and at day 5.

At day 5, mice received an intravenous injection of 250µl phosphate buffered saline containing 23.8 µCi of [H^3] methyl thymidine. Approximately five hours later, mice were killed by CO₂-inhalation, and the draining auricular lymph nodes were removed and

weighed. After preparing a single cell suspension for each mouse, cells were precipitated by TCA and the radioactivity was determined (incorporation of [H^3] methyl thymidine in the pellets) by means of liquid scintillation counting as disintegration per minute (dpm). The mean dpm per treated group was determined and the stimulation index (test item compared to the concurrent vehicle control) was calculated.

Results

Based on the data provided in the certificate of analysis a sufficient solubility and stability of the test item in the solvent used (DMSO) can be assumed.

The mean stimulation indices revealed no differences to the concurrent vehicle control group at any test concentration. Mean stimulation indices of 1.0, 0.9, 1.0 and 0.9 were obtained for the 4 test concentrations of 0.5, 1.5, 5 and 10%, respectively. Thus, no EC3 value (equal to the concentration inducing a stimulation index of 3) was calculated since all stimulation indices were below 3.

The responses noted do not indicate a skin sensitising potential of 4-nitrophenylaminoethylurea.

The positive control (PPD, 1% in DMSO) caused a stimulation index of 7.0 which demonstrated the sensitivity of the test system used.

Conclusion

4-Nitrophenylaminoethylurea induced no immune response in local lymph nodes after dermal application to the mouse ear using DMSO as vehicle. Consequently, no EC3 value was calculated and 4-nitrophenyl aminoethylurea is considered not to be a skin sensitisier under the described test conditions.

Ref.: 20

3.3.4. Dermal / percutaneous absorption

Percutaneous absorption *in vitro* (Study 1: Non-oxidative formulation)

Guideline:	OECD 428 (2004)
Tissue:	Porcine back and flank skin (thickness: $960 \pm 70 \mu\text{m}$)
Method:	Diffusion Teflon-chambers
Test substance:	Nitrogelb (WR 23348) tested at a concentration of 0.5 % in a typical non-oxidative hair dye formulation
Batch:	110889 (sample R96003805; lot 131004-100)
Purity:	99.5%
Dose:	0.5 mg/cm ² tested as part of a non-oxidative formulation
No. of chambers:	6 (five for the formulation containing the test item and one for the blank formulation)
Duration/exposure:	Single application for 60 min
GLP:	In compliance

The skin absorption of Nitrogelb at the maximum concentration intended for non-oxidative hair colorants was investigated with pig skin (Schweizer Edelschwein, female, 110 kg) prepared from the back and the flanks ($960 \pm 70 \mu\text{m}$ thick). 2 mg of the dye was applied to the skin in a commercial hair dye formulation (400 mg aqueous cream formulation containing 0.5% dye applied to 4 cm² skin).

The integrity of the skin was monitored at the beginning of the experiment using tritiated water. A diffusion Teflon-chamber was used. The receptor solution (physiological phosphate buffer containing NaCl and antibiotics) was pumped through the receptor chamber at a rate of 5 ml/h. Sixty minutes after substance application, the test item was removed by washing the skin twice with 4 ml water, once with 4 ml washing solution (shampoo-formulation) and again twice with water. The washing solutions were combined and the amount of dye was determined by HPLC.

Fractions of the receptor fluid were collected after 16, 24, 40, 48, 64 and 72 hours and stored at -20°C until analysis. At termination of the experiment, the skin was heat-treated and the upper skin compartment (stratum corneum and upper stratum germinativum, referred to as epidermis) was mechanically separated from the lower skin compartment (lower stratum germinativum and upper dermis, referred to as upper dermis). The two skin compartments were extracted separately and the dye content quantified by means of HPLC analysis.

Results

The limit of detection was 0.2 ng/HPLC injection and the limit of quantification was 1 ng/HPLC injection.

Based on the data for solubility (28.7 mg/ml in receptor fluid) and stability (\geq 7 days in water-based systems) provided in the report, the substance is considered stable.

The integrity of each skin preparation was demonstrated by examination of penetration characteristics with tritiated water. The figures obtained (0.65 to 1.44% of the applied dose found in the receptor fluids) were all within the limit of acceptance (\leq 1.5%).

The total recovery of $96.1 \pm 1.0\%$ of the applied dose confirmed the validity of the test. The majority of 4-Nitrogelb remained on the skin surface representing $96.2 \pm 1.1\%$ ($480.9 \pm 5.2 \mu\text{g}/\text{cm}^2$) of the applied dose.

After 72h a cumulative amount of $0.02 \pm 0.02 \mu\text{g}/\text{cm}^2$ (range 0.00 to 0.06) was determined in the receptor fluid. The figures for the upper dermis and the epidermis were $0.03 \pm 0.01 \mu\text{g}/\text{cm}^2$ (range 0.02 to 0.03) and $0.19 \pm 0.06 \mu\text{g}/\text{cm}^2$ (range 0.11 to 0.26). The absorption kinetics indicate that the small amounts of Nitrogelb remaining on the skin after the washing steps tend to migrate to deeper layers, and thus might act as a reservoir. Therefore, the dye content in the epidermis was considered to become potentially bioavailable.

Conclusion

Under the described test conditions, a mean skin penetration of $0.24 \pm 0.07 \mu\text{g}/\text{cm}^2$ was obtained for Nitrogelb by summing up the amounts for receptor fluid, dermis and epidermis. The maximum skin penetration was $0.31 \mu\text{g}/\text{cm}^2$.

Ref: 21

Percutaneous absorption *in vitro* (Study 2: oxidative formulation)

Guideline:	OECD 428 (2004)
Tissue:	Porcine back and flank skin (thickness: $900 \pm 100 \mu\text{m}$)
Method:	Diffusion Teflon-chambers
Test substance:	Nitrogelb (WR 23348) tested at a concentration of 0.25 % in an oxidative hair dye formulation (3 % hydrogen peroxide)
Batch:	110889 (sample R96003805; lot 131004-100)
Purity:	99.5%
Concentration:	0.25 mg/cm ² tested as part of an oxidative formulation
No. of chambers:	6 (five for the formulation containing the dye stuff and one for the blank formulation) number of animals not mentioned
Duration/exposure:	Single application for 60 min
GLP:	In compliance

The skin absorption of Nitrogelb at the maximum concentration intended for oxidative hair colorants, was investigated with pig skin (Schweizer Edelschwein, male, 110 kg) prepared from the back and the flanks ($900 \pm 100 \mu\text{m}$ thick).

1 mg of the dye was applied to the skin in a commercial hair dye formulation (400 mg formulation containing 0.25% dye and 3% hydrogen peroxide applied to 4 cm² skin surface).

The integrity of the skin was monitored at the beginning of the experiment using tritiated water. A diffusion Teflon-chamber was used. The receptor solution (physiological phosphate buffer containing NaCl and antibiotics) was pumped through the receptor chamber at a rate of 5 ml/h.

Sixty minutes after substance application, the test item was removed by washing the skin twice with 4 ml water, once with 4 ml washing solution (shampoo-formulation) and again twice with water. The washing solutions were combined and the amount of dye was determined by HPLC.

Fractions of the receptor fluid were collected after 16, 24, 40, 48, 64 and 72 hours and stored at -20°C until analysis. At termination of the experiment, the skin was heat-treated and the upper skin compartment (stratum corneum and upper stratum germinativum, referred to as epidermis) was mechanically separated from the lower skin compartment (lower stratum germinativum and upper dermis, referred to as upper dermis). The two skin compartments were extracted separately and the dye content quantified by means of HPLC analysis.

Results

The limit of detection was 0.2 ng/HPLC injection and the limit of quantification was 1 ng/HPLC injection. Based on the data for solubility (28.7 mg/ml in receptor fluid) and stability the substance is considered stable for the given test procedure.

The integrity of each skin preparation was demonstrated by examination of penetration characteristics with tritiated water. Figures of 1.3 to 2.1% of the applied dose were obtained. All 5 skin samples treated with the dye formulation were within the limit of acceptance ($\leq 1.5\%$). The single skin with a value of 2.1% was chosen as background control.

The mean recovery of the test item was 96.84%. The vast majority of Nitrogelb remained on the skin surface representing $96.79 \pm 4.87\%$ (0.242 ± 0.012 mg/cm²) of the applied dose.

After 72 hours, the cumulative content of the test item in the receptor fluid was 0.01 ± 0.01 µg /cm² (range 0.00 to 0.02). In the upper dermis and in the epidermis, 0.02 ± 0.01 µg/cm² (range 0.01 to 0.03) and 0.07 ± 0.07 µg/cm² (range 0.02 to 0.19) were measured, respectively. The absorption kinetics indicate that the small amounts of Nitrogelb remaining on the skin after the washing steps tend to migrate to deeper layers and might act as a reservoir. Therefore, the dye content in both the upper dermis and the epidermis was considered as potentially bioavailable.

Conclusion

Under the described test conditions, a skin penetration of 0.1 ± 0.07 µg/cm² was obtained for Nitrogelb by summing up the amounts for receptor fluid, upper dermis and epidermis. The maximum skin penetration was 0.22 µg/cm².

Ref.: 22

Comment on percutaneous absorption studies *in vitro*

At 0.5% in a non-oxidative formulation, the maximum penetration of Nitrogelb through porcine skin was 0.31 µg/cm². At 0.25% in an oxidative formulation it was 0.22 µg/cm². However, the experiment was not performed according to the SCCP Notes of Guidance (only five replicates from one donor; 100 mg formulation/cm² applied instead of 20 mg/cm²).

Percutaneous absorption *in vivo*

Guideline:	/
Species/strain:	Rat, strain Sprague Dawley Him:OFA, SPF
Group size:	3 per sex and treatment group
Test substance:	(Ureidogelb); ^{14}C -4-nitrophenylaminoethyl urea (ring-labelled)
Radioactive purity:	>97%
Batch:	/
Dose levels:	Application area: 9 cm ² A) 0.25% commercial formulation <i>without</i> hydrogen peroxide: equal to 0.28 mg/cm ² B) 0.25% commercial formulation <i>with</i> hydrogen peroxide: equal to 0.28 mg/cm ² C) 0.83% solution in DMSO/water (1:0.69) equal to 0.29 mg/cm ²
Dosing schedule:	Single cutaneous application for 0.5 h; total study period 72 h
GLP:	In compliance

^{14}C -4-Nitrophenylaminoethyl urea was applied dermally to groups of three male and three female rats (body weight about 200 g at the day of application). The application area was 9 cm² and the test substance was applied at concentrations of 0.83% in DMSO (equal to 0.29 mg/cm²). Commercial hair dye formulations containing 0.25% of the test item (equal to 0.28 mg/cm²) were applied either in the absence or in the presence of hydrogen peroxide. The contact time was 30min. Application was performed under anaesthesia.

The test substance was scraped off (formulation only) and the skin was rinsed with a shampoo solution (about 100 ml) and warm water. After rinsing, the area was covered with gauze and an air permeable plastic cone to further prevent licking of the treated area during the 72 h observation period.

Animals were killed 72 h after the application. Application sites, blood and numerous organs were analysed for radioactivity. The radioactivity in the remaining carcass was also determined after complete removal of the skin.

Results

Satisfactory recovery rates (98 to 107.9%) were obtained. The majority of the applied dose (97.7 to 107.6% of the applied amount) was recovered in the washing solutions for all groups.

For the DMSO solution, the amount of radioactivity remaining at the application site (skin) was 0.381 µg/cm² (equal to 0.131 ± 0.0393% of the applied dose). The respective figures for formulations without and with hydrogen peroxide were 0.89 µg/cm² (equal to 0.317 ± 0.150% of the applied dose) and 1.06 µg/cm² (equal to 0.377 ± 0.221% of the applied dose).

The mean amounts absorbed (sum of amounts detected in urine, faeces, and residual carcass) were low for the hair dye formulations: 0.048 µg/cm² (equal to 0.017 ± 0.007% of the applied dose) in the absence of hydrogen peroxide, and 0.037 µg/cm² (equal to 0.013 ± 0.006% of the applied dose) in the presence of hydrogen peroxide. The respective figure for the DMSO solution was 0.298 µg/cm² (equal to 0.103 ± 0.100% of the applied dose).

Elimination of the absorbed test substance occurred mainly via urine (78 to 79%). The elimination via urine was fast, as 58-91% of the absorbed amount were excreted within the first 24 hours. Excretion via faeces was generally of less importance (0.002 to 0.032%).

After 72 h, the remaining amount of ^{14}C -4-nitrophenylaminoethyl urea detected in the carcass was close to or below the detection limit of 0.003% of the applied dose for all three

groups. The concentrations in the organs were generally low (below or close to the detection limit). Taking the mean amounts in urine, faeces, residual carcass and the total content of the dye remaining in the skin as potentially bioavailable, cutaneous absorption rates of 0.938 µg/cm² (equal to 0.334%) and 1.097 µg/cm² (equal to 0.390%) were found for commercial formulations without and with hydrogen peroxide, respectively, applied under typical use conditions. The respective figures for the DMSO solution were 0.679 µg/cm² (equal to 0.234%) of the applied dose. The higher amounts noted for formulations compared to DMSO may be due to less efficient washing steps following application of the formulations, leading to higher residues in the skin of the application site.

Conclusion

¹⁴C-4-Nitrophenylaminoethyl urea applied dermally to rats in a semipermanent and in an oxidative hair dye formulation as well as in DMSO/water is mainly excreted via urine and to a minor extent via faeces. Excretion via urine was fast, with approximately 75% of the absorbed dose being excreted within the first 24 hours. Low tissue residue levels distributed through the general carcass were found independent of the vehicle used, suggesting that bio-accumulation is not to be expected following dermal exposure. Based on the conservative assumption that the total amount found in the skin will become completely bioavailable, mean absorption rates of 1.097 µg/cm² and 0.938 µg/cm² were obtained for ¹⁴C-4- nitrophenylaminoethyl urea when applied in a commercial formulation under typical use conditions in the presence or absence of hydrogen peroxide, respectively. In DMSO, the respective value was 0.679 µg/cm².

Ref.: 24

Comment

In the absence of valid *in vitro* studies, the above values of 1.097 µg/cm² and 0.938 µg/cm² respectively in the presence and absence of hydrogen peroxide may be used for the calculation of the Margin of Safety.

3.3.5. Repeated dose toxicity

3.3.5.1. Repeated Dose (28 days) oral / dermal / inhalation toxicity

No data submitted

3.3.5.2. Sub-chronic (90 days) oral / dermal / inhalation toxicity

Guideline:	OECD 408 (1998)
Species/strain:	Rat, strain Sprague Dawley CFY
Group size:	10 per sex and dose
Test substance:	4-nitrophenylaminoethylurea
Batch:	110889
Purity:	98.9% (HPLC, 254 nm)
Dose levels:	1, 5, 25 and 125 mg/kg bw
Vehicle:	Bi-distilled water (containing 1% CMC)
Route:	Oral, gavage
Exposure period:	13 weeks, 7 days/week
GLP:	In compliance

The objective of this study was to determine the toxicity of the test item following daily oral administration (by gavage) to 10 Sprague Dawley rats per sex and dose for 13 consecutive weeks. A control group consisting of 10 Sprague Dawley rats per sex was treated with the vehicle alone. The four dose groups received 1, 5, 25 and 125 mg/kg bw of 4-nitrophenylaminoethylurea.

Morbidity/mortality checks were performed at least twice daily and clinical signs were recorded daily. Additional clinical examinations were performed weekly. Individual body weights and food consumption were recorded weekly.

Behavioural and functional tests as well as laboratory investigations were performed in week 13. Ophthalmological examinations were carried out before the start of the treatment and repeated in week 13.

At the end of the treatment period, all animals were killed and selected organs were weighed. Tissue samples were fixed and preserved at necropsy for all animals. Selected tissues from all animals were examined histopathologically.

Results

Homogeneity and concentrations of the suspensions of *4-nitrophenylaminoethylurea* in the vehicle were analytically confirmed. The mean concentrations of the test samples (analysed three to four times during the treatment period) were 102.5%, 101.6%, 94.8% and 93% of the nominal values of the 4 dose groups, confirming the proper dosing.

Orally administered *4-nitrophenylaminoethylurea* in the dose range of 1 to 125 mg/kg bw was well tolerated by the rat. There were no unscheduled deaths in any dose group. Treatment-related changes, i.e. discolouration of the fur at dose levels of 5 mg/kg bw and above and coloured urine at all dose levels were noted. These findings were not considered as adverse effects, but a common finding for dyes. Body weight gain and food consumption were unaffected by treatment at all dose levels.

There were no effects of treatment at any dose level on the behavioural and functional tests performed. No treatment-related ocular lesions were noted at any dose level.

Treatment-related effects on the haematological profile occurred in both sexes at 125 and 25 mg/kg bw after 13 weeks. The effect at 125 mg/kg bw was considered a mild anaemia characterised by small reductions in RBC count, haemoglobin concentration and packed cell volume (males only), with increased MCV and reticulocyte count. Similar but weaker effects were evident in both sexes at 25 mg/kg bw. Erythrocyte-related parameters were unaffected by treatment at 1 mg/kg bw and 5 mg/kg bw. Furthermore, no treatment-related effect was noted on total and different WBC counts at any dose level.

Apart from colouration, no treatment-related effects were noted with regard to urinalysis or serum clinical chemistry.

No treatment-related gross abnormalities were found at necropsy at any dose level, apart from staining of the fur. There was a treatment-related increase in the spleen weights of both sexes at 125 mg/kg bw, but not at the lower dose levels. The mean kidney weight of females at 125 mg/kg bw was increased, mainly due to two animals with pronounced mineralisation or pyelonephritis. No other treatment-related effects on organ weights were observed at any dose level.

Treatment-related histopathological alterations occurred in the spleen and the bone marrow in association with the above described reductions in red blood cell parameters. In the spleen, a slightly increased incidence and severity of extramedullary haemopoiesis was evident in both sexes at 25 or 125 mg/kg bw, associated with increased haemosiderosis in both sexes at 125 mg/kg bw and in females at 25 mg/kg bw. The increased extramedullary haemopoiesis and haemosiderosis were considered to represent a response to a haemolytic anaemia. A slight decrease in the amount of fatty tissue seen in the femoral bone marrow of a few animals at 125 mg/kg bw also suggested a regenerative response of the bone marrow.

Conclusion

In conclusion, the haemopoietic system was identified as a target organ for *4-nitrophenylaminoethylurea* based on the occurrence of anaemia and adaptive responses in the spleen and in the bone marrow at dose levels of 25 or 125 mg/kg bw. The "No observed adverse effect level" (NOAEL) was 5 mg/kg bw/d.

Ref.: 25

3.3.5.3. Chronic (> 12 months) toxicity

No data submitted

3.3.6. Mutagenicity / Genotoxicity

Bacterial gene mutation assay

Guideline:	OECD 471 (1983)
Species/strain:	<i>Salmonella typhimurium</i> , TA1535, TA1537, TA98, TA100 and TA1538
Replicates:	Three plates per concentration in two independent experiments
Assay conditions:	Direct plate incorporation method, both in the presence and absence of Aroclor 1254 induced rat liver S9-mix.
Test substance:	LGH 110583/2 (4-nitrophenylaminoethylurea)
Batch:	LEH 5/2
Purity:	96.5 area% (HPLC, 254 nm)
Concentrations:	Exp. 1: 1, 10, 100, 300, 1000, 2000, 3000, 4000 and 5000 µg/plate Exp. 2: 100, 300, 1000, 3000 and 5000 µg/plate Exp. 3: 300, 1000, 2000, 3000, 4000 and 5000 µg/plate (TA100 and TA1538 only)
Solvent:	DMSO
GLP:	In compliance

4-nitrophenylaminoethylurea was tested for mutagenicity in the *Salmonella*/microsome assay both with and without Aroclor 1254 induced rat liver S9-mix. Negative (solvent) and positive controls were included in all experiments in accordance with OECD guidelines.

Results

From 3000 µg/plate and above precipitation as fine crystals in the aqueous agar-medium was observed. Toxicity measured as reduced background growth was observed at all concentrations in the presence and absence of S9-mix in strains TA1535, TA1537 and TA98. For strains TA1538 and TA100 reduced background growth was noted only at low test concentrations (1 to 1000 µg/plate) with and without a metabolic activation system. A concentration related and reproducible increase in revertant colony numbers was observed in TA100 and TA1538 in three independent experiments. No mutagenic effects was observed in the strains TA1535, TA1537 and TA98 up to a concentration of 5000 µg/plate, either with or without S9-mix. All positive controls used gave a distinct increase of induced revertant colonies.

Conclusion

Under the experimental conditions used in this study, 4-nitrophenylaminoethylurea was genotoxic (mutagenic) in the bacterial reverse mutation test.

Ref.: 26

Remarks

A further bacterial gene mutation assay was part of a former submission. As this test reveals several limitations with regard to technical performance and as unspecified test material was used, the study is not presented here in detail. Result: No mutagenic activity was seen either with or without metabolic activation.

Mammalian Cell Gene Mutation Test in Mouse Lymphoma Cells (tk locus)

Guideline:	OECD 476 (1997)
Species/strain:	Mouse lymphoma cell line L5178Y (tk locus)
Replicates:	Duplicate cultures in two independent experiments

Opinion on 4-nitrophenyl aminoethylurea

Metabolic activation:	phenobarbital/β-naphthoflavone induced rat liver S9-mix
Test substance:	4-nitrophenylaminoethylurea
Batch:	110889
Purity:	98.9 area% (HPLC, 254 nm)
Concentrations:	Experiment I: 43.8, 87.5, 175.0 and 350.0 µg/ml with and without metabolic activation Experiment II: 21.9, 43.8, 87.5, 175.0 and 350.0 µg/ml with and without metabolic activation
Treatment:	Incubation time was 4 hours in the presence and 24 hours in the absence of S9-mix. The expression period was 72 hours after 4 h treatment and 48 h after 24 h treatment
Solvent:	DMSO
GLP:	In compliance

4-nitrophenylaminoethylurea was evaluated for its genotoxic activity at the *tk* locus in the mouse lymphoma cell line L5178Y. In a range-finding toxicity test the highest applied concentration (700 µg/ml) was based on the maximum solubility in the culture medium. The main test was performed as two independent experiments using duplicate cultures. Incubation time was 4 hours in the presence and 24 hours in the absence of S9-mix. DMSO was used as solvent control, while methylmethanesulphonate (MMS, 13 µg/ml) and cyclophosphamide (CPA, 3 µg/ml) were used as positive controls without and with metabolic activation system, respectively. Mutant frequency, colony size and cell survival (measured as relative suspension growth (RSG) and relative total growth (RGT) were determined

Results

In the initial range-finding study, concentrations up to 700 µg/ml with and without S9-mix were evaluated for toxicity. No relevant toxic effects were observed up to the maximum concentration at both treatment intervals. Due to heavy precipitation at 700 µg/ml at the end of the incubation period, 350 µg/ml was considered the maximum analysable concentration in the main experiments.

In the main experiment, precipitation occurred at 175.0 µg/ml and above in the absence and presence of metabolic activation. No marked cytotoxicity was observed in the main study in the presence of S9-mix, but higher concentrations could not be tested due to precipitation of the test item. In experiment II (24 hours) without metabolic activation a concentration dependent toxic effect was observed. RTG was 20.8 and 29.5% at the highest concentration tested in the two cultures, respectively.

In the first experiment, the mutant frequency exceeded the laboratory negative control range at 350 µg/ml. However, this effect was only observed in one culture, and the induction factor was only 1.3 and therefore not considered biological relevant. In the second experiment without S9-mix and 24 hours treatment, there was a more than twofold increase in mutant frequency at 87.5 and 350 µg/ml. However, the mutant frequency remained within the historical control range, it was not concentration related and was only observed in one culture and therefore considered biological irrelevant. It was concluded that no biologically relevant or dose-dependent increase in the number of mutant colonies was noted in the presence or absence of S9-mix up to the maximum test concentration compared to the concurrent controls and the historical control range. The concurrent positive controls induced a distinct increase in mutant frequency.

Conclusion

Under the test conditions used in this study 4-nitrophenylaminoethylurea was not considered to be genotoxic (mutagenic and/or clastogenic) in mammalian cells, neither in the absence nor in the presence of metabolic activation.

Ref: 27

Remarks

In a former submission, a further mouse lymphoma assay (1983) was included. This test is of limited validity as e.g. non-standard test conditions were applied and unspecified test material was used and is therefore not considered relevant for the hazard assessment of 4-nitrophenylaminoethylurea.

Result: No mutagenic effects were observed.

***In vitro* chromosome aberration test**

Guideline:	/
Replicates:	replicate cultures
Cells:	CHO cells
Test substance:	4-(β-ureidoethyl)-aminonitro-benzol (LGH 11 0583/2)
Solvent:	DMSO
Batch:	/
Purity:	99.9%
Concentrations:	5, 25 and 50 µg/ml (with S9-mix) 25, 50 and 250 µg/ml (with S9-mix)
Treatment:	24 h followed immediately by harvest in the absence of S9-mix. 2 h treatment and harvest time 24 h after start of treatment in the presence of S9-mix
GLP:	present but not signed

4-(β-ureidoethyl)-aminonitro-benzol has been investigated in the absence and presence of metabolic activation for the induction of chromosomal aberrations in CHO cells. Test concentrations were based on the results of a preliminary toxicity test with doses from 5 to 0.0005 mg/ml measuring mitotic index. The highest doses selected for the main experiment showed about 50% inhibition of growth compared to the DMSO control.

In the absence of S9-mix, cells were treated for 24 h and immediately harvested; in the presence of S9-mix, cells were treated for 2 h and harvested 24 h after the start of treatment. Three h before harvest, each culture was treated with colchicine (final concentration 0.25×10^{-6} M) to block cells at metaphase of mitosis. Liver S9 fraction from Aroclor 1254-induced rats was used as exogenous metabolic activation system.

Toxicity was not determined in the main test. Chromosome (metaphase) preparations were stained with Giemsa and examined microscopically for chromosomal aberrations. 100 metaphases were scored from each of the two replicates per dose. Negative and positive controls were included.

Results

In the preliminary toxicity test without S9-mix 43% inhibition of the mitotic index was found at 50 µg/ml, with S9-mix 45% inhibition at 250 µg/ml. These doses were selected as the top doses for the main experiment.

Both in the presence and the absence of S9-mix, 4-(β-ureidoethyl)-aminonitro-benzol did not induce a biological relevant increase in the number of cells with chromosomal aberrations. In both the absence and the presence of S9-mix, 4-(β-ureidoethyl)-aminonitro-benzol did not cause an increase in polyploidy.

Conclusion

Under the test conditions used in this study 4-(β-ureidoethyl)-aminonitro-benzol was not considered to be genotoxic (clastogenic) in CHO cells, neither in the absence nor in the presence of metabolic activation.

Ref.: 9 (subm I)

Comment

Although this test is not performed according the current guideline, the batch number is not given, a repeat experiment was not performed, and a signed GLP statement was absent, the study indicates the absence of clastogenic potential in mammalian cells *in vitro*.

3.3.6.2 Mutagenicity/Genotoxicity *in vivo*

Mouse bone marrow micronucleus test

Guideline:	OECD 474 (1997)
Species/strain:	Mouse, strain NMRI
Group size:	6 males per test group and sacrifice time (5 animals per test group were analysed)
Test substance:	4-nitrophenylaminoethylurea
Batch:	110889
Purity:	98.9 % (HPLC, 254 nm)
Dose level:	250, 500 and 1000 mg/kg bw administered as single doses
Route:	Intraperitoneal
Vehicle:	30 % DMSO/ 70 % corn oil
Sacrifice times:	24 after dosing and 48 hours (high dose and control only)
GLP:	In compliance

The clastogenic/aneugenic potential of 4-nitrophenylaminoethylurea was investigated in bone marrow cells of mice. Single doses were administered intraperitoneally in a total volume of 10 ml/kg bw. For the high dose, two groups were treated to allow sampling after 24 and 48 hours.

Dose selection was based on findings in the pre-experiment for toxicity, in which a dose range of 100 to 1500 mg/kg bw was administered.

Bone marrow cells were sampled from mice immediately after sacrifice, 24 h or 48 h (high dose group only) after dosing. At least 2000 PCEs per animal were analysed. Toxicity on the bone marrow was measured as the ratio between polychromatic and normochromatic erythrocytes (PCE/NCE ratio) for each animal. Five animals per test group were evaluated. Negative control groups received 30% DMSO / 70% corn oil (10 ml/kg bw) and concurrent positive control groups received 40 mg/kg bw cyclophosphamide (CPA) dissolved in deionised water

Results

In the pre-experiment (2 animals per sex and dose), intraperitoneal administration of 1250 mg/kg bw and of 1500 mg/kg bw 4-nitrophenylaminoethylurea caused death within 24 hours in one male and two males, respectively. No deaths were noted in females at those doses. Signs of toxic reactions were abdominal position, eyelid closure, ruffled fur, apathy, convulsion and reduced spontaneous activity. Furthermore, the urine of all animals was yellow (the colour could be clearly distinguished from the normal urine colour) up to 48 hours after administration. At the 4 remaining doses, ranging from 100 to 1000 mg/kg bw, no deaths occurred after intraperitoneal administration. Apart from yellow discoloured urine, no further clinical signs were noted up to 48 hours.

Based on these findings, doses of 250, 500 and 1000 mg/kg bw were chosen for the main study. As in the pre-test, no substantial difference was observed in sensitivity/toxicity to the test item between sexes; in the main test only male mice were used.

In the main study, toxic signs like those described in the pre-experiment were noted for the high dose group up to 24 hours after administration, but no cases of death occurred. Yellow discoloured urine was noted up to 24 and 48 hours (highest dose level only) after intraperitoneal administration.

4-nitrophenylaminoethylurea showed no clear cytotoxic effect in the bone marrow as the PCE/NCE ratio did not substantially change after treatment with the test item up to systemically toxic doses. However, the discoloured urine and the observed systemic toxicity and the available kinetic data indicate that 4-nitrophenylaminoethylurea becomes bio-available and systemically distributed after intraperitoneal administration.

There was no statistically significant or biologically relevant increase in the number of micronuclei per 2000 PCEs in the mice of any of the 4-nitrophenylaminoethylurea treated groups versus the respective vehicle control groups.

The positive control group (CPA) produced a statistically significant increase in micronucleated PCEs and the vehicle control was well within the range of historical control data of the performing laboratory.

Conclusion

4-nitrophenylaminoethylurea was not genotoxic (clastogenic and/or aneugenic) in the *in vivo* micronucleus test using NMRI mice after a single intraperitoneal administration up to 1000 mg/kg bw.

Ref.: 28

In vivo unscheduled DNA synthesis (UDS) test

Guideline:	OECD 486 (1997)
Species/strain:	Rat, strain Wistar HsdCpb: WU (SPF)
Group size:	4 male rats per dose group and per sacrifice time
Test substance:	4-Nitrophenylaminoethylurea
Batch:	110889
Purity:	98.9 area % (HPLC, 254 nm)
Dose levels:	1000 and 2000 mg/kg bw
Route:	Oral, gavage
Dose volume:	20 ml/kg bw (10 ml/kg bw for positive controls)
Vehicle:	30% DMSO + 70% PEG 400
Sacrifice times:	4 and 16 hours after treatment
GLP:	In compliance
Date:	August 7, 2008 - June 29, 2009 (end in-life phase: October 2008)

4-Nitrophenylaminoethylurea was investigated for the induction of unscheduled DNA synthesis (UDS) in hepatocytes of rats. The test solutions of 4-nitrophenylaminoethylurea were prepared freshly immediately before administration. Stability for the single application of test material in this study can be assumed based on results from prior stability evaluations in DMSO as well as aqueous vehicles.

Test concentrations were based on acute toxicity in a pre-experiment test with 2 animals per sex/group. The animals were treated orally and examined at intervals of 1, 2-4, 6 and 24 h after administration of the test item. Based on these findings and the limit dose recommended by the OECD guideline, 1000 and 2000 mg/kg bw were chosen for both the 4 h and the 16 h treatment. The animals received 4-nitrophenylaminoethylurea once and were examined for acute toxic symptoms at intervals of approximately 1, 2, 4 (4 h treatment group only) and 16 h (16 h treatment group only) after administration of the test item.

Hepatocytes for UDS analysis were collected 4 h and 16 h after administration of 4-nitrophenylaminoethylurea. Cell viability was determined by the trypan blue dye exclusion method. At least 90 minutes after plating the cells were incubated for 4 h with 5 µCi/ml ³H-thymidine (specific activity 20 Ci/mmol) followed by overnight incubation with unlabelled thymidine. Evaluation of autoradiography was done after 14 days.

UDS was reported as nuclear grain counts, cytoplasmic grain counts and net nuclear grain counts (nuclear minus cytoplasmic grains). Increased net grains should be based on enhanced nuclear counts rather than on decreased cytoplasmic counts. The mean and percentage of cells in repair (defined as cells with a net grain count of at least +5) was reported separately for each animal. Unscheduled synthesis was determined in 50 randomly selected hepatocytes/slide on 2 replicate slides per rat. Heavily radiolabelled cells undergoing replicative DNA synthesis were excluded from counting. Negative and positive controls were in accordance with the OECD guideline.

Results

Both in the pre- and main experiment, all animals showed reduction in spontaneous activity and ruffled fur immediately after treatment up to 24 h. At 6 and 24 h in the pre-experiment and at 4 and 16 h after treatment in the main experiment the rats had yellow or brown urine.

Cell viability after hepatocyte isolation was not substantially affected due to the *in vivo* treatment with 4-nitrophenylaminoethylurea at any of the treatment periods or dose groups. The inter-individual variations obtained for the numbers and the viabilities of the isolated hepatocytes were in the range of the historical laboratory control data.

The systemic distribution of 4-nitrophenylaminoethylurea and the bioavailability in the target tissue could be demonstrated by the observation of discoloured urine in the treated rats.

Neither a biological relevant increase in the number of nuclear grains, the mean net nuclear grain count nor in the percentage of cells in repair as compared to the untreated control was found in hepatocytes of any treated animal both for the 4 h and the 16 h treatment time. Treatment of the animals with the positive controls DMH (80 mg/kg bw) and 2-AAF (100 mg/kg bw) induced distinct increases in the number of nuclear and net grain counts, indicating the sensitivity of the test method used.

Conclusion

Under the experimental conditions 4-nitrophenylaminoethylurea did not induce unscheduled DNA synthesis and, consequently, is not genotoxic in rats in the *in vivo* UDS test.

Ref.: 7 (subm. III)

3.3.7. Carcinogenicity

No data submitted

3.3.8. Reproductive toxicity

3.3.8.1. Two generation reproduction toxicity

No data submitted

3.3.8.2. Teratogenicity

Guideline:	OECD 414 (2001)
Species/strain:	Rat, strain Wistar Crl:Wi/Br (SPF)
Group size:	25 pregnant females per dose group
Test substance:	4-nitrophenylaminoethylurea
Batch:	110889
Purity:	98.9% (HPLC, 254 nm)
Dose levels:	50, 250 and 600 mg/kg bw
Route:	Oral, gavage
Vehicle:	1% carboxymethylcellulose in bi-distilled water
Dosing schedule:	Days 6 to 19 of gestation
GLP:	In compliance

Three groups of 25 mated females received 4-nitrophenylaminoethylurea at dose levels of 50, 250 and 600 mg/kg bw by gavage from day 6 to day 19 of gestation. An equally sized group receiving the vehicle (1% carboxymethylcellulose in bi-distilled water) alone served as control.

Clinical condition and reaction to treatment were recorded at least once daily. Body weights and food consumption were reported/calculated for days 0, 6, 9, 12, 15, 18 and 20 of gestation. All surviving females were sacrificed on day 20 of gestation for examination of

their uterine contents, including examination of the placenta. At necropsy, the dams were examined macroscopically and live foetuses were weighed, sexed and examined for external, visceral and skeletal abnormalities.

Approximately one half of the foetuses was examined for skeletal malformations. The remaining foetuses did undergo a visceral examination.

Results

One female at 600 mg/kg bw was found dead on day 12 of gestation. Three females in this dose group and one receiving 250 mg/kg bw were killed in a moribund condition between days 14 and 17 of gestation. All the decedents had severe weight loss. There was no mortality in the control and the low dose groups.

All rats in the treated groups had abnormally yellow-discoloured urine throughout the treatment period. Most of the females in all treated groups had a yellow-stained fur after several days of treatment. There were no other clinical signs amongst the surviving females of any dose group.

There was a marked decrease in body weight gain and reduced food consumption throughout the treatment period for females dosed with 600 mg/kg bw. A slight decrease was also evident in the 250 mg/kg bw group. The 50 mg/kg bw group was not affected.

There were no treatment-related macroscopic findings at the terminal necropsy examination of the adult females.

The percentage post-implantation loss and mean live litter size was comparable in the treated and control groups. The foetal sex ratios did not show any treatment-related trends. Compared to the control group, foetal weight was significantly reduced at dose levels of 250 (-10 %) and 600 mg/kg bw (-20%). Consistent with the reduced foetal weight, an increased incidence of foetuses with reduced ossification was observed. Since clear signs of systemic toxicity were noted in the dams, effects in foetuses are regarded as a secondary reaction to maternal toxicity.

Nine foetuses from a single high dose litter had anasarca and cleft palate and one foetus from a litter given 250 mg/kg bw had an anophthalmia. These malformations are common spontaneous findings and were within the historical background for the rat strain at the testing facility. Due to the isolated nature of these malformations, they were not considered to be test item related.

No adverse effects were observed in the low dose group (50 mg/kg bw).

Conclusion

Treatment of females with 4-nitrophenylaminoethylurea at 600 mg/kg bw resulted in severe maternal toxicity including deaths and in corresponding embryo-foetal toxicity, i.e. reduction in the foetal weight and reduction of foetal ossification, but with no influence on embryo-foetal survival. At 250 mg/kg bw, less severe maternal toxicity and only slight reductions in foetal weight (-10%) and in ossification were noted.

The low dose level of 50 mg/kg bw of 4-nitrophenylaminoethylurea was the NOAEL for both maternal and embryo-foetal toxicity.

Ref.: 29

3.3.9. Toxicokinetics

No data submitted

3.3.10. Photo-induced toxicity

3.3.10.1. Phototoxicity / photoirritation and photosensitisation

No data submitted

3.3.10.2. Phototoxicity / photomutagenicity / photoclastogenicity

No data submitted

3.3.11. Human data

No data submitted

3.3.12. Special investigations

Guideline:	/
Cells:	Human intestinal epithelial cell line TC-7
Test substance:	4-nitrophenylaminoethylurea
Batch:	110889
Purity:	98.9 % (HPLC, 254 nm)
Test concentration:	50 µM in HBSS buffer containing 1 % DMSO
Incubation time:	60 min
GLP:	Not in compliance, but QAU checked

The bioavailability of 4-nitrophenylaminoethylurea across the intestinal barrier was investigated in human intestinal epithelial (TC-7) cells *in vitro*. The permeability from the apical (A, pH 6.5) to the basolateral (B, pH 7.4) side was investigated at 37°C in 96-well transwell plates with shaking for a 60 min contact time. Analysis of the donor (apical) and receiver (basolateral) samples was done by means of HPLC-MS/MS and the apparent permeability coefficient (P_{app}) was calculated for two independent experiments. ^{14}C -mannitol (about 4 µM) was used to demonstrate the integrity of the cell monolayer. Only monolayers revealing a permeability of $< 2.5 \times 10^{-6}$ cm/sec were used. Propranolol and ranitidine were analysed concurrently to demonstrate the validity of the test system.

According to the laboratory's classification system, a low permeability is considered for test items revealing a $P_{app} < 2 \times 10^{-6}$ cm/sec. A P_{app} of $2 - 20 \times 10^{-6}$ cm/sec and a $P_{app} \geq 20 \times 10^{-6}$ cm/sec classify a substance to have a moderate and a high permeability, respectively. Ranitidine, which has a 50 % absorption in humans was used as low permeability reference compound, as recommended by FDA.

Results

The figures for the reference substances propranolol ($P_{app} = 25.9 \times 10^{-6}$ cm/sec), a high permeability reference compound with 90 % absorption in humans, and ranitidine ($P_{app} = 0.2 \times 10^{-6}$ cm/sec) revealing an absorption rate of about 50 % in humans were well within the acceptance range of $20 - 45 \times 10^{-6}$ cm/sec and $0.2 - 2 \times 10^{-6}$ cm/sec, respectively, and demonstrated the validity of the assay.

4-nitrophenylaminoethylurea revealed a P_{app} of 17.0×10^{-6} cm/sec and thus was classified to be of medium permeability, indicating a substantial absorption from the gastro-intestinal tract.

Ref.: 30

3.3.13. Safety evaluation (including calculation of the MoS)**CALCULATION OF THE MARGIN OF SAFETY****4-nitrophenyl aminoethylurea****(Oxidative conditions)**

Absorption through the skin (in vivo) A	=	1.097 µg/cm²
Skin Area surface	=	580 cm²
Dermal absorption per treatment	=	0.64 mg
Typical body weight of human	=	60 kg
Systemic exposure dose	=	0.01 mg/kg bw/d
No observed adverse effect level (90-day, oral, rat)	=	5 mg/kg bw/d

Margin of Safety	NOAEL / SED	=	500
-------------------------	--------------------	---	------------

The value obtained for dermal absorption under non-oxidative conditions ($0.938 \mu\text{g}/\text{cm}^2$) was comparable to the one used in the calculation above, resulting in a similar MoS. Therefore only the calculation with the higher value under oxidative conditions is given.

3.3.14. Discussion*Physico-chemical specifications*

4-Nitrophenyl aminoethylurea is used as direct dye in semi-permanent hair formulations at a maximum on-head concentration of 0.5%, and as a hair colouring agent (direct dye) in oxidative hair dye formulations at a maximum on-head concentration of 0.25%.

4-Nitrophenyl aminoethylurea is a secondary amine, and thus, it is prone to nitrosation. The nitrosamine content in 4-nitrophenyl aminoethylurea is not reported. 4-Nitrophenyl aminoethylurea should not be used in combination with nitrosating agents. Several small peaks were seen in HPLC, and these were tentatively identified as derivatives of 4-Nitrophenyl aminoethylurea. N-(2-aminoethyl)-4-nitroaniline was present at more than 1% in batch LEH5/2. This substance is a secondary amine. (*The applicant stated that LEH 5/2 is an old batch from 1983*) The content of N-(2-aminoethyl)-4-nitroaniline in other batches was <0.22%.

General toxicity

In the rat sub-chronic (90 days) oral toxicity study the haemopoietic system was identified as a target organ for 4-nitrophenyl aminoethylurea based on the occurrence of anaemia and adaptive responses in the spleen and in the bone marrow at dose levels of 25 or 125 mg/kg bw. The no observed adverse effect level (NOAEL) was 5 mg/kg bw/day.

In the rat teratogenic study, treatment of females with 4-nitrophenyl aminoethylurea at 600 mg/kg bw resulted in severe maternal toxicity including deaths and in corresponding embryo-foetal toxicity. At 250 mg/kg bw, less severe maternal toxicity and only slight reductions in foetal weight (-10 %) and in ossification were noted. A dose level of 50 mg/kg bw of 4-nitrophenylaminoethylurea was the NOAEL for both maternal and embryo-foetal toxicity.

Irritation / sensitisation

4-Nitrophenyl aminoethylurea applied neat was not irritant to rabbit skin but was irritant to rabbit eyes.

4-Nitrophenyl aminoethylurea induced no immune response in local lymph nodes after dermal application to the mouse ear using DMSO as vehicle. Consequently, no EC3 value was calculated and 4-nitrophenyl aminoethylurea was evaluated as not being a skin sensitisier.

Dermal penetration

In the absence of valid *in vitro* studies, the values of 1.097 µg/cm² and 0.938 µg/cm² derived from the *in vivo* studies in rats, respectively in the presence and absence of hydrogen peroxide, may be used for the calculation of the Margin of Safety.

Mutagenicity / Genotoxicity

Overall, the genotoxicity of 4-nitrophenyl aminoethylurea is sufficiently investigated for the three endpoints of genotoxicity: gene mutations, chromosome aberrations and aneuploidy. Treatment with 4-nitrophenyl aminoethylurea resulted in an induction of gene mutations in bacteria. In mammalian cells (mouse lymphoma assay), no potential to induce gene mutations or chromosomal aberrations was found. The absence of a clastogenic potential of 4-nitrophenyl aminoethylurea in mammalian cells *in vitro* was further supported by the negative results of a chromosome aberration test in CHO cells. In addition, no clastogenic/aneugenic effects were noted in an *in vivo* micronucleus test in mice. In this study, the occurrence of discoloured urine and the observed signs of systemic toxicity indicate the systemic availability of 4-nitrophenyl aminoethylurea. The positive effect found in the gene mutation test in bacteria was not confirmed in an *in vivo* test. Exposure to 4-nitrophenyl aminoethylurea did not result in unscheduled DNA synthesis in an UDS test in rats. As positive effects found *in vitro* were not confirmed in *in vivo* tests, 4-nitrophenyl aminoethylurea can be considered to have no *in vivo* genotoxic potential and additional tests are unnecessary.

Carcinogenicity

No data submitted

4. CONCLUSION

Based on the data provided, the SCCS is of the opinion that the use of 4-nitrophenyl aminoethylurea with a maximum on-head concentration of 0.25% in oxidative and 0.5% in non-oxidative hair dye formulations does not pose a risk to the health of the consumer.

4-Nitrophenyl aminoethylurea is a secondary amine. It should not be used in combination with nitrosating substances. The nitrosamine content should be < 50 ppb.

5. MINORITY OPINION

Not applicable

6. REFERENCES

Submission I, 1990

9. Garner, R.C. Study to evaluate the chromosome damaging potential of LGH 110583/2 by its effects on cultured Chinese hamster ovary cells using an *in vitro* cytogenetics assay. Microtest Research Limited, UK YO1 5DU Heslington, York. Study number HAZ 3/CYT/RCG1. 26 July 1983.

Submission II, 2005

1. Tenberken-Pötzsch, B.; Identity and purity of Nitrogelb; *WELLA AG*; 2004
2. Umbrecht, G.; Data concerning definition of structure of 4-Nitrophenyl Aminoethylurea; *COSMITAL SA*; 2005
3. Dougoud, P.; Certificate of analysis for 4-NITROPHENYLAMINOETHYLUREA (NITROGELB, B070); *COSMITAL SA*; 2003
4. Lenz; Partition coefficient Nitrogelb; *BIOCHEMA*; 1992
5. Lenz; Water solubility Nitrogelb; *BIOCHEMA*; 1992
6. Lenz; Melting point Nitrogelb; *BIOCHEMA*; 1992
7. Lenz; Boiling point Nitrogelb; *BIOCHEMA*; 1992
8. Lenz; Relative density Nitrogelb; *BIOCHEMA*; 1992
9. Lenz; Vapour pressure curve Nitrogelb; *BIOCHEMA*; 1992
10. Lenz; Surface tension (Aqueous Solution) Nitrogelb; *BIOCHEMA*; 1992
11. Lenz; Inflammability (solids) Nitrogelb; *BIOCHEMA*; 1992
12. Lenz; Explosive properties Nitrogelb; *BIOCHEMA*; 1992
13. Lenz; Auto-flammability (solids) Nitrogelb; *BIOCHEMA*; 1992
14. Lenz; Flame supporting properties Nitrogelb; *BIOCHEMA*; 1992
15. Opinion of the Scientific Committee on Cosmetology concerning 1-(2'-Ureidoethyl)-amino-4-nitro-benzene Colipa-no. B 70; *SCC*; 1992
16. Weide, J.; Acute oral toxicity test of 1-(2'-Ureidoethyl)-amino-4-nitrobenzene; *WELLA AG*; 1984
17. Klein, W.; Acute dermal toxicity of "Nitrogelb" in rats (Limit-Test); *SEIBERSDORF*; 1992
18. Cuthbert, J. A.; Nitrogelb: Acute dermal irritation test in rabbits; *IRI*; 1991
19. Cuthbert, J. A.; Nitrogelb: Acute eye irritation test in rabbits; *IRI*; 1991
20. Ravel, G.; 4-Nitrophenylaminoethylurea WR 23348 - Local lymph node assay; *MDS PHARMA SERVICES*; 2004
21. Beck, H.; Cutaneous absorption of 0.5% Nitrogelb (=WR23348) in a typical hair dye formulation through pig skin *in vitro*; *COSMITAL SA*; 2005
22. Beck, H.; Cutaneous absorption of 0.25% 4-Nitrophenylaminoethylurea (=WR23348) in a typical hair dye formulation with peroxide through pig skin *in vitro*; *COSMITAL SA*; 2005
23. Simon, G. A.; Maibach, H. I.; The pig as an experimental animal model of percutaneous permeation in man: Qualitative and quantitative observations - An overview; *SKIN PHARMACOL. PHYSIOL.*; 13, 229-234; 2000
24. Hofer, H.; Percutaneous absorption of 1-(2'-Ureidoethyl)-amino-4-nitrobenzene ("Ureidogelb"); *SEIBERSDORF*; 1985
25. Ravel, G.; 4-Nitrophenyl Aminoethylurea (WR23348) - 13 week oral (gavage) toxicity study in the rat; *MDS PHARMA SERVICES*; 2005
26. Faller, C.; Assessment of the potential mutagenicity of 4-Nitro-N-(2'-Ureidoethyl)anilin in the Ames reversion assay with *Salmonella Typhimurium*; *COSMITAL SA*; 1993
27. Poth, A.; Cell mutation assay at the Thymidine Kinase locus (TK+/-) in mouse lymphoma L5178Y cells with WR23348 Nitrogelb B070 ; *RCC-CCR*; 2004

Opinion on 4-nitrophenyl aminoethylurea

28. Honarvar, N.; Micronucleus assay in bone marrow cells of the mouse with 4-Nitrophenyl aminoethylurea (WR23348); *RCC-CCR*; 2005
29. Ravel, G.; 4-Nitrophenyl aminoethylurea (WR23348) - Prenatal development study by the oral route (gavage) in the pregnant rat (segment II); *MDS PHARMA SERVICES*; 2005
30. McVean, M.; ADME: A-B Permeability - Study of 4-nitrophenylaminoethylurea; *CEREP*; 2004
31. König, P.; Data base search for references for B070 - 4-Nitrophenyl Aminoethylurea: 27080-42-8; *WELLA AG*; 2005

Submission III, 2010

1. COLIPA Submission to the Scientific Committee on Consumer Products (Submission III) in answer to SCCP opinion SCCP/1037/06 on 4-NITROPHENYLAMINOETHYLUREA, June 2010
2. COLIPA. Technical Guidance Document on Minimising and Determining Nitrosamines in Cosmetics. December 2008
3. Challis B.C. et al. A screening procedure for total N-nitroso contaminants in personal care products: results of collaborative studies undertaken by a CTPA Working Group. International Journal of Cosmetic Science 17, 219-231 (1995)
4. Ruess W. Comparison of two batches of Nitrogelb by LC/DAD/MS Request no: A 2004/323 - follow up work. RD-ANC, 12.05.2010
5. Stability test report Nitrogelb
6. Purity and content of 2-((4-Nitrophenyl)amino)ethylurea
7. Honarvar N. et al. *In vivo* Unscheduled DNA Synthesis in Rat Hepatocytes with 4-nitrophenyl aminoethylurea (WR23348). COSMITAL SA, CH-1723 Marly. Study number 1189711. 29 June 2009